Digital therapeutics company The Digital Therapeutics Alliance (DTA) said on Monday that it plans to explore the development of appropriate standards and guidelines for digital therapeutics in collaboration with the independent non-profit healthcare organisation, USP.
DTA reportedly hosted a roundtable discussion on 31 May 2018 at USP headquarters in Rockville, MD. The roundtable included stakeholders who shared their perspectives on the future of digital therapeutics and the collaboration with USP, as well as their concerns with quality in this area.
Through the partnership, the companies will explore ways to safeguard product quality and integrity for digital therapeutics, with input from relevant stakeholders. If areas of need are identified, any development of standards or guidelines will follow USP's usual, rigorous public processes.
From device and medication sensors to patient-focused applications and software, digital therapeutics strengthens current clinical interventions and disease management options for patients with diabetes, asthma, heart disease, substance abuse, pain, sleep disturbances as well as other conditions.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project